Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic
Bella Mehta, Jane E. Salmon, Said A. Ibrahim
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has created a global public health crisis and severe economic disruption. There are currently no effective therapies to prevent, treat, or cure COVID-19. To meet this need, the scientific community has mobilized to develop vaccines and drugs to prevent and treat COVID-19. Trials are underway to assess the effectiveness of existing drugs that hold promise in treating COVID-19. While the results of these trials are eagerly awaited, the US Food and Drug Administration recently authorized use of chloroquine and hydroxychloroquine for emergency treatment of COVID-19.
Topics & Concepts
HydroxychloroquinePandemicCoronavirus disease 2019 (COVID-19)Economic shortageMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusSystemic lupus erythematosus2019-20 coronavirus outbreakVirologyDiseaseIntensive care medicineInfectious disease (medical specialty)Internal medicineOutbreakLinguisticsGovernment (linguistics)PhilosophySystemic Lupus Erythematosus ResearchCOVID-19 Clinical Research StudiesDrug-Induced Ocular Toxicity